Latest Capital Funding News

Bailador Technology Investments is backing DASH Technology Group with an additional $5 million investment at a valuation below its current carrying value, reflecting cautious optimism amid market pressures.

Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

GreenTech Metals has appointed James Rattenbury as CEO to spearhead development of its Munni Munni platinum group metals project, signalling a strategic push in the West Pilbara mining hub.

Macquarie Group has reported a solid third quarter for FY26, with significant profit gains in asset management and capital divisions, alongside steady growth in banking services. The group maintains a strong capital buffer, positioning itself well despite a cautious economic outlook.

Shares of Apiam Animal Health Limited (ASX – AHX) have been suspended from trading following court approval of its acquisition by entities controlled by Adamantem Capital Fund II. This marks a significant ownership change for the animal health company.

Apiam Animal Health’s acquisition scheme by Adamantem Capital has been legally approved, leading to the suspension of its shares on the ASX. Key dates for dividend payments and scheme implementation are now set.

The Supreme Court of New South Wales has approved the scheme of arrangement for Adamantem Capital Fund II’s acquisition of Apiam Animal Health, marking a pivotal step toward the deal’s completion and the suspension of Apiam shares on the ASX.

Apiam Animal Health has announced a fully franked special dividend of 10 cents per share, payable before the completion of its proposed acquisition by Adamantem Capital entities. The dividend is conditional on the scheme’s effectiveness and offers shareholders potential tax benefits through franking credits.

Strickland Metals has successfully raised A$55 million through an institutional placement to accelerate exploration and advance a Pre-Feasibility Study at its Rogozna Project in Serbia.

Strickland Metals has announced a $55 million institutional placement to fund an expanded drilling program and advance a Pre-Feasibility Study for its Rogozna gold project in Serbia, with major shareholders reaffirming their support.

Apiam Animal Health shareholders have overwhelmingly approved the proposed acquisition by Adamantem Capital-controlled entities, clearing a critical hurdle for the $500 million deal.